Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. DOD Biotech PCL's accounts receivables for the quarter that ended in Jun. 2026 was ฿71.6 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
DOD Biotech PCL's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 53.44.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. DOD Biotech PCL's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was ฿0.04.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
DOD Biotech PCL's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), DOD Biotech PCL's accounts receivable are only considered to be worth 75% of book value:
DOD Biotech PCL's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
DOD Biotech PCL Accounts Receivable Related Terms
DOD Biotech PCL Accounts Receivable Historical Data
* Premium members only.
The historical data trend for DOD Biotech PCL's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of ฿71.6 Mil mean?
DOD Biotech PCL (BKK:DOD-R) has a Accounts Receivable of ฿71.6 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on DOD Biotech PCL and its competitors.
Is DOD Biotech PCL's Accounts Receivable too high?
DOD Biotech PCL's current Accounts Receivable is ฿71.6 Mil. Overall, DOD Biotech PCL has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's Accounts Receivable compare to KHC and GIS?
DOD Biotech PCL's Accounts Receivable of ฿71.6 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Consumer Packaged Goods company?
A good Accounts Receivable depends on the Consumer Packaged Goods industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on DOD Biotech PCL and its competitors. DOD Biotech PCL's current Accounts Receivable is ฿71.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
DOD Biotech PCL (BKK:DOD-R) has a current Accounts Receivable of ฿71.6 Mil. The stock's GF Value™ is ฿1.52, compared to a current price of ฿0.97 — trading 36.4% below its estimated fair value. The current Accounts Receivable is ฿71.6 Mil. DOD Biotech PCL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD-R), the current Accounts Receivable is ฿71.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DOD Biotech PCL (BKK:DOD-R) Overvalued in 2026?
Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued.
The current stock price of ฿0.97 is trading 36.4% below its estimated GF Value™ of ฿1.52.
Key valuation signals for BKK:DOD-R:
Accounts Receivable: ฿71.6 Mil
GF Value™: ฿1.52 vs. price of ฿0.97 (36.4% below fair value)
No single metric tells the full story. See the BKK:DOD-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
67GF Score
Get the complete analysis for BKK:DOD-R
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:DOD-R has been successfully added to your 
